QUALITY OF LIFE BENEFIT IN ANEMIC CANCER PATIENTS TREATED WITH NEORECORMON (EPOETIN BETA): QUALITY OF LIFE TREATMENT RESPONSE AND CLINICAL EVALUATION OF ONCE-WEEKLY DOSING
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Clinical: Hematological response - increase in hemoglobin of at least 2 g/dL within the previous 6 weeks.
Baseline, 3-4 weeks, 6-8 weeks, 10-12 weeks and 14-16 weeks after study start
Russia: Ministry of Health of Russian Federation